News

Integrating Immunotherapy In Treatment for Patients With Triple-Negative Breast Cancer

Immunotherapy /

Triple-negative breast cancer (TNBC) is an aggressive form lacking estrogen, progesterone, and HER2 receptors, which historically limited treatment to chemotherapy. Recent advances in immunotherapy have transformed care, especially because TNBC tumors are often more immunogenic, with higher levels of tumor-infiltrating lymphocytes and PD-L1 expression that make them responsive to immune-targeting treatments. Checkpoint inhibitors are the […]

Integrating Immunotherapy In Treatment for Patients With Triple-Negative Breast Cancer Read More »

Magnetodrone Technology: Precision-Guided Cancer Therapy at the Microscale

Technology Innovation /

Magnetodrone technology is a new, precision-guided cancer therapy that uses microscopic, self-propelled bacteria to deliver drugs directly into solid tumors. This innovative approach aims to overcome a major limitation of traditional treatments: the inability of drugs to effectively reach and penetrate the entire volume of a tumor. How Magnetodrones Work The Magnetodrones: These are non-pathogenic,

Magnetodrone Technology: Precision-Guided Cancer Therapy at the Microscale Read More »

Mitomycin Intravesical Solution: A New Standard for Recurrent Low-Grade Bladder Cancer

Molecular Oncology /

Recurrent low-grade, intermediate-risk non-muscle-invasive bladder cancer (LG-IR-NMIBC) has traditionally required repeated TURBT surgeries due to high recurrence rates, placing significant physical and emotional burdens on patients. Elderly patients, in particular, face frequent procedures under anesthesia and ongoing surveillance, which can severely impact quality of life. FDA-approved Zusduri (mitomycin intravesical solution) now provides the first non-surgical

Mitomycin Intravesical Solution: A New Standard for Recurrent Low-Grade Bladder Cancer Read More »

Multiparametric MRI improves prostate cancer detection

Diagnostics /

Multiparametric MRI’s positive predictive value for detecting prostate cancer improves when lower apparent diffusion coefficient (ADC) values and patient prostate-specific antigen density (PSAD) thresholds data are incorporated, investigators have found. Multiparametric MRI :1. T2-weighted imaging (T2WI): High-resolution anatomical detail, especially useful for identifying tumor boundaries, 2. Diffusion-weighted imaging (DWI): Detects restricted water movement in tissues, which often correlates

Multiparametric MRI improves prostate cancer detection Read More »

New BRAF-Mutated Colorectal Cancer Treatment

Targeted Therapy /

New first-line therapy has transformed treatment for BRAF V600E–mutated metastatic colorectal cancer (mCRC), an aggressive subtype with historically poor outcomes. FDA approval of the triple combination—encorafenib, cetuximab, and mFOLFOX6—marks a major breakthrough for these patients. The BREAKWATER trial demonstrated that this regimen doubled overall survival to 30.3 months compared with 15.1 months for standard therapy,

New BRAF-Mutated Colorectal Cancer Treatment Read More »

Advanced Cystoscopy for Early Bladder Cancer Diagnosis

Diagnostics /

New imaging techniques are improving cancer detection during cystoscopy, helping doctors identify and remove tumors more accurately. Blue Light Cystoscopy (BLC) with Cysview uses a photosensitizing agent, hexaminolevulinate HCl, instilled into the bladder about an hour before the procedure. Cancer cells absorb the agent and glow bright pink or red under blue light, while healthy

Advanced Cystoscopy for Early Bladder Cancer Diagnosis Read More »

New MRI Method Boosts Prostate Cancer Accuracy

Technology Innovation /

Investigators have found that multiparametric MRI (mpMRI) for prostate cancer becomes more accurate when lesion-level apparent diffusion coefficient (ADC) values and patient prostate-specific antigen density (PSAD) thresholds are incorporated. Stanford researchers reported their findings on August 12 in Radiology, showing that these additional metrics can improve the positive predictive value (PPV) of mpMRI for clinically

New MRI Method Boosts Prostate Cancer Accuracy Read More »

Advanced techniques in treatment of non-invasive bladder cancer

Treatment /

Recent advances in non-muscle-invasive bladder cancer (NMIBC) offer several innovative therapies, particularly for patients unresponsive to BCG treatment. These options leverage gene therapy, immune stimulation, oncolytic viruses, and novel drug delivery systems to improve outcomes. Nadofaragene firadenovec is an FDA-approved gene therapy that delivers a modified virus into bladder cells, prompting them to produce interferon

Advanced techniques in treatment of non-invasive bladder cancer Read More »

Breaking New Ground: Innovative Therapies Transforming Muscle-Invasive Bladder Cancer Treatment

Treatment /

Recent advances in muscle-invasive bladder cancer (MIBC) have expanded treatment options, particularly for high-risk and metastatic disease. Combination therapy with Enfortumab vedotin and Pembrolizumab is now a first-line option for advanced bladder cancer. Enfortumab vedotin delivers chemotherapy directly to tumor cells, while pembrolizumab activates the immune system to recognize and attack cancer. Adjuvant immunotherapy with

Breaking New Ground: Innovative Therapies Transforming Muscle-Invasive Bladder Cancer Treatment Read More »

New Technology in Early Diagnosis of Blaccer Cancer

Diagnostics /

Recent innovations in bladder cancer diagnostics are improving detection, monitoring, and treatment planning while reducing invasive procedures. Contrast-enhanced ultrasound (CEUS) uses microbubble agents to visualize blood flow within tumors, helping distinguish non-invasive from invasive bladder cancers. Advances like 3D CEUS are also being explored to evaluate tumor response during therapy. Advanced imaging with PET-CT or

New Technology in Early Diagnosis of Blaccer Cancer Read More »